Perflutren

Evidence Level: L5 Predicted Indications: 50

Quick Overview

Item Value
Drug Name Perflutren
DrugBank ID DB00556
Brand Names (EU) Optison
Evidence Level L5
Predicted Indications 50
Top Prediction Score 97.47%

Approved Indication (EMA)

This medicinal product is for diagnostic use only. Optison is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left-ventricular-endocardial-border delineation with resulting improvement in wall-motion visualisation. Optison should only be used in patients where the study without contrast enhancement is inconclusive.

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 acute intermittent porphyria 97.47% DL
2 nephrogenic syndrome of inappropriate antidiuresis 96.56% DL
3 multidrug-resistant tuberculosis 96.50% DL
4 myocardial ischemia 96.34% DL
5 acute neonatal citrullinemia type I 96.00% DL
6 adult-onset citrullinemia type I 96.00% DL
7 coronary artery disease 95.70% DL
8 anomalous left coronary artery from the pulmonary artery 95.48% DL
9 tuberculoma 95.30% DL
10 tuberculous ascites 95.30% DL
11 tuberculosis, avian 95.30% DL
12 inactive tuberculosis 95.30% DL
13 tuberculosis, bovine 95.21% DL
14 chronic tic disorder 94.13% DL
15 urea cycle disorder 94.05% DL
16 extrapyramidal and movement disease 94.00% DL
17 benign shuddering attacks 94.00% DL
18 porphyria 93.97% DL
19 psychogenic movement disorders 93.77% DL
20 benign paroxysmal tonic upgaze of childhood with ataxia 93.77% DL

Showing top 20 of 50 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.